229 related articles for article (PubMed ID: 31932841)
1. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
Zhang X; Wang X; Wang XQD; Su J; Putluri N; Zhou T; Qu Y; Jeong M; Guzman A; Rosas C; Huang Y; Sreekumar A; Li W; Goodell MA
Blood; 2020 Mar; 135(11):845-856. PubMed ID: 31932841
[TBL] [Abstract][Full Text] [Related]
2. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
[TBL] [Abstract][Full Text] [Related]
4. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
[TBL] [Abstract][Full Text] [Related]
5. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
6. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
Loberg MA; Bell RK; Goodwin LO; Eudy E; Miles LA; SanMiguel JM; Young K; Bergstrom DE; Levine RL; Schneider RK; Trowbridge JJ
Leukemia; 2019 Jul; 33(7):1635-1649. PubMed ID: 30692594
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
[TBL] [Abstract][Full Text] [Related]
8. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
[TBL] [Abstract][Full Text] [Related]
9. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifiers in normal and malignant hematopoiesis.
Haladyna JN; Yamauchi T; Neff T; Bernt KM
Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
[TBL] [Abstract][Full Text] [Related]
11. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation.
Celik H; Mallaney C; Kothari A; Ostrander EL; Eultgen E; Martens A; Miller CA; Hundal J; Klco JM; Challen GA
Blood; 2015 Jan; 125(4):619-28. PubMed ID: 25416276
[TBL] [Abstract][Full Text] [Related]
12. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation.
Mayle A; Yang L; Rodriguez B; Zhou T; Chang E; Curry CV; Challen GA; Li W; Wheeler D; Rebel VI; Goodell MA
Blood; 2015 Jan; 125(4):629-38. PubMed ID: 25416277
[TBL] [Abstract][Full Text] [Related]
13. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
14. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
DiNardo CD; Patel KP; Garcia-Manero G; Luthra R; Pierce S; Borthakur G; Jabbour E; Kadia T; Pemmaraju N; Konopleva M; Faderl S; Cortes J; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2014 Aug; 55(8):1925-9. PubMed ID: 24138309
[No Abstract] [Full Text] [Related]
15. Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer.
Li WL; Xiao MS; Zhang DF; Yu D; Yang RX; Li XY; Yao YG
Gene; 2014 Aug; 546(2):263-70. PubMed ID: 24887488
[TBL] [Abstract][Full Text] [Related]
16. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
17. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
18. DNMT3A in Leukemia.
Brunetti L; Gundry MC; Goodell MA
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
[TBL] [Abstract][Full Text] [Related]
19. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion.
Tovy A; Reyes JM; Gundry MC; Brunetti L; Lee-Six H; Petljak M; Park HJ; Guzman AG; Rosas C; Jeffries AR; Baple E; Mill J; Crosby AH; Sency V; Xin B; Machado HE; Castillo D; Weitzel JN; Li W; Stratton MR; Campbell PJ; Wang H; Sanders MA; Goodell MA
Cell Stem Cell; 2020 Aug; 27(2):326-335.e4. PubMed ID: 32673568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
